CPT has been highly critical of the exclusive marketing provisions in the US and the proposed EU orphan drug acts. Pharmaceutical companies now obtain 20 year patents for inventions, and investments in clinical trials and other research required for drug… Continue Reading
CONFIDENTIAL RELEASED IN FULL CONFIDENTIAL PTQ1906 PAGE 01 GENEVA 03470 01 OF 09 271621Z ACTION 10-00 425261 271705Z /38 O 271615Z MAY 98 FM USMISSION GENEVA TO SECSTATE WASHDC IMMEDIATE 6208 INFO IO COLLECTIVE AMEMBASSY LONDON AMEMBASSY BRASILIA AMEMBASSY BUENOS… Continue Reading
A Free Trade Area For The Americas: A Consumer Perspective On Proposals As They Relate To Rules Regarding Intellectual Property Comments for the Working Group On Intellectual Property Rights, Third Trade Ministerial and Americas Business Forum, Belo Horizonte, Brazil, May… Continue Reading
Call for More Reliable Costs Data on Clinical Trials James Love January 13, 1997Abstract The following is an article titled “Call for More Reliable Costs Data on Clinical Trials,” Published in the January 13, 1997 issue of the Marketletter, on… Continue Reading
Comments on Trade and Pharmaceutical Policies: A Perspective from the U.S. Consumer Movement HAI Seminar: World Trade Organization/GATT, Pharmaceutical Policies and Essential Drugs October 4, 1996 Bielefeld, Germany James Love Center for Study of Responsive Law (1) I would like… Continue Reading
Comments Presented to the Second NIH CRADA Forum September 8, 1994 James Love Director, Taxpayer Assets Project P.O. Box 19367, Washington, DC 20036 I. Introduction My name is James Love. I work for the Center for Study of Responsive Law,… Continue Reading
Pharmaceutical Drugs, Intellectual Property Rights and Public Health: A Consumer Perspective from the United States James Packard Love* Presented at XV Asamblea General de la Asociaión Latinoamericana de Industrias Farmacéuticas San Carlos de Bariloche – Río Negro – Argentina 11… Continue Reading
(More on this topic here: https://www.keionline.org/orphan-drugs and here.) This is from: United States Senate, Committee on the Judiciary, Subcommittee on Antitrust, Monopolies and Business Rights, Anticompetitive Abuse of the Orphan Drug Act: Invitation to High Prices, January 21, 1992, Serial… Continue Reading